Clinical Data Celgene Corporation announced the results from its 72-week RADIANCE trial of ozanimod on patients with relapsing multiple sclerosis.  "RADIANCE met its primary efficacy endpoint — reduction in the cumulative number of total gadolinium-enhancing (GdE) lesions, as determined by MRI, from week 12 to week 24."  For placebo patients switched after week 24 to either dose of ozanimod, the mean number of GdE lesions was decreased by 90 to 95 percent compared with that at week 24.